Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study Evaluating the Role of Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer

NCT05302778 is registered in ClinicalTrials.gov with University of Milano Bicocca as lead sponsor.

NCT NCT05302778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05302778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study Evaluating the Role of Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer
Lead sponsor
University of Milano Bicocca
Phase
Observational
Overall status
Unknown status
Start date
March 22, 2021
Completion date
December 31, 2023
Enrollment
200 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastatic breast cancer, triple negative breast cancer